NABI BIOPHARMACEUTICALS : IPXL

Profil supprimé

23 juin 2011 •01:06

CA 2010 : 879,5 mlns $
Evolution CA : +145.4%
RN 2010 : 250,4 mlns $

Regardez moi le Graph (le pattern ressemble bcp à celui de CGEN) ; je pense qu'il y a de quoi ramasser ...

Dernier Cours ($) 20.53
CB (mlns $) 1,310,000
Revenus 2010 (mlns $) 879.51
Budget R&D 2010 (mlns $) 86.22
Résultat Net 2010 (mlns $) 250.42
Cash (mlns $) 349,960
Nbre titres (mlns) 65000
Cash par titre ($) 5.38
Autonomie Cash (mois) 87
Dettes totales (mlns $) 0.00
CASH/CB (%) 27%
Valo Pipeline (mlns $) 960,040
Prochains Résu financiers 2/9-Aug-11
Derniers Résu financiers 3-May-11


Evolution sur 3 Mois -13.80%
Evolution sur 6 Mois -1.30%
Evolution sur 12 Mois -3.20%
Plus haut sur 1an ($) 28.75
Plus bas sur 1an ($) 14.7
MM 50 jours ($) 25.18
MM 200 jours ($) 23.65
Volume moyen (3 mois) 716686
Volatilité (Beta) 0.57
Consensus Analystes Hold
Part des instit. (% K) 78.03
Short Ratio (jours) 10
Short (% du K) 8.80%
Nombre d'Employés 918


> A PROPOS DE IPXL >

Impax Laboratories is betting that its pharmaceuticals will make a positive impact its own financial health. The company makes specialty generic pharmaceuticals, which it markets through its Global Pharmaceuticals division and through marketing alliances with other firms, including Teva. It concentrates on controlled-release versions of various generic versions of branded and niche pharmaceuticals that require difficult-to-obtain raw materials or specialized expertise. Additionally, the company's branded pharmaceuticals business (Impax Pharmaceuticals) is developing andimproving upon previously approved drugs that target Parkinson's disease, multiple sclerosis, and other central nervous system disorders